3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
9
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Colonic Neoplasms
5
Breast Neoplasms
5
Adenocarcinoma
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Renal Cell
4
Urethral Neoplasms
3
Rectal Neoplasms
3
Liver Neoplasms
3
Esophageal Neoplasms
3
Urinary Bladder Neoplasms
2
Ureteral Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Malignant Solid Tumor
2
Carcinoma, Transitional Cell
2
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
Cisplatin
38
Fluorouracil
37
Radiotherapy
33
Oxaliplatin
23
Paclitaxel
20
Irinotecan
18
Leucovorin
17
Docetaxel
17
Capecitabine
10
Neoadjuvant Therapy
9
Surgical Procedures, Operative
8
Cetuximab
8
Chemotherapy, Adjuvant
7
Radiation
6
Carboplatin
6
Immunohistochemistry
5
Erlotinib Hydrochloride
5
Biopsy
5
Magnetic Resonance Spectroscopy
4
Gene Expression Profiling
4
Folfox protocol
4
Epirubicin
4
Drug Therapy
4
pembrolizumab
3
Trastuzumab
3
Microarray Analysis
3
Gefitinib
3
Fluorodeoxyglucose F18
3
Endoscopy, Digestive System
3
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma Of Esophagus
×
Ramucirumab
×
Clear all
NCT04499924
2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3
Completed
17 enrolled
23 charts